Browse the corpus

Rhinitis and nasal congestion: Oral: Capsule: Brompheniramine 4 mg and pseudoephedrine 60 mg: One capsule every 4-6 hours (maximum: 4 capsules/24 hours) Liquid: Brompheniramine 1 mg and pseudoephedrine 15 mg per 5 mL: 20 mL every 6 hours (maximum: 80 mL/24 hours) Brompheniramine 4 mg and pseudoephedrine 20 mg per 5 mL: 5 mL every 4-6 hours (maximum: 30 mL/24 hours) Dosing: Pediatric (For additional information see "Brompheniramine and pseudoephedrine: Pediatric drug information" )

Rhinitis and nasal congestion: Oral: Capsule: Children ≥12 years: Refer to adult dosing. Liquid: Brompheniramine 1 mg and pseudoephedrine 7.5 mg per 1 mL: Children 2 to <6 years: 1 mL every 4-6 hours (maximum: 6 mL/24 hours) Children 6-12 years: 2 mL every 4-6 hours (maximum: 12 mL/24 hours) Brompheniramine 1 mg and pseudoephedrine 15 mg per 5 mL: Children 6-11 years: 10 mL every 6 hours (maximum: 40 mL/24 hours) Children ≥12 years: Refer to adult dosing. Brompheniramine 4 mg and pseudoephedrine 20 mg per 5 mL: Children 6-11 years: 2.5 mL every 4-6 hours (maximum: 15 mL/24 hours) Children ≥12 years: Refer to adult dosing. Dosing: Geriatric Refer to adult dosing. Dosage Forms: U.S. Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product Capsule, oral: Lodrane® D: Brompheniramine maleate 4 mg and pseudoephedrine hydrochloride 60 mg Liquid, oral: Brotapp: Brompheniramine maleate 1 mg and pseudoephedrine hydrochloride 15 mg per 5 mL (120 mL, 240 mL, 480 mL) [ethanol free, sugar free; contains propylene glycol, sodium benzoate; grape flavor] LoHist PSB: Brompheniramine maleate 4 mg and pseudoephedrine hydrochloride 20 mg per 5 mL (473 mL) [dye free, ethanol free, sugar free; cherry flavor] Q-Tapp Cold & Allergy: Brompheniramine maleate 1 mg and pseudoephedrine hydrochloride 15 mg per 5 mL (118 mL, 237 mL) [ethanol free; contains propylene glycol, sodium 2 mg/5 mL, sodium benzoate; grape flavor] Liquid, oral [drops]: J-Tan D PD: Brompheniramine maleate 1 mg and pseudoephedrine hydrochloride 7.5 mg per 1 mL (30 mL) [dye free, ethanol free, sugar free; contains propylene glycol; cotton candy flavor] Generic Equivalent Available: U.S. Yes Use Temporary relief of symptoms associated with seasonal and perennial allergic rhinitis, the common cold, or sinusitis Adverse Reactions Significant Frequency not defined. Cardiovascular: Arrhythmias, flushing, hypertension, pallor, palpitation, tachycardia Central nervous system: Convulsions, CNS stimulation, dizziness, excitability (children; rare), giddiness, hallucinations, headache, insomnia, irritability, lassitude, nervousness, sedation Gastrointestinal: Anorexia, diarrhea, dyspepsia, nausea, vomiting, xerostomia Genitourinary: Dysuria, urinary retention (with BPH) Neuromuscular skeletal: Tremors, weakness Ocular: Diplopia Renal: Polyuria Respiratory: Respiratory difficulty

Central nervous system: Convulsions, CNS stimulation, dizziness, excitability (children; rare), giddiness, hallucinations, headache, insomnia, irritability, lassitude, nervousness, sedation Gastrointestinal: Anorexia, diarrhea, dyspepsia, nausea, vomiting, xerostomia Genitourinary: Dysuria, urinary retention (with BPH) Neuromuscular skeletal: Tremors, weakness Ocular: Diplopia Renal: Polyuria Respiratory: Respiratory difficulty Contraindications Hypersensitivity to brompheniramine, pseudoephedrine, or any component of the formulation; concomitant MAO inhibitor therapy (or 2 weeks following MAO inhibitor use) Warnings/Precautions

Disease-related concerns: • Asthma: Use with caution in patients with a history of asthma. • Cardiovascular disease: Use with caution or avoid in patients with cardiovascular disease (including hypertension and ischemic heart disease). • Diabetes: Use with caution in patients with diabetes mellitus. • Increased intraocular pressure: Use with caution in patients with increased intraocular pressure. • Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction. • Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.

Other warnings/precautions: • Self-medication (OTC use): When used for self-medication (OTC), notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever. Discontinue and contact healthcare provider if nervousness, dizziness, or sleeplessness occur. Metabolism/Transport Effects None known. Drug Interactions (For additional information: Launch Lexi-Interact™ Drug Interactions Program ) Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial. Risk C: Monitor therapy Aclidinium: May enhance the anticholinergic effect of Anticholinergics. Risk X: Avoid combination Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Risk C: Monitor therapy Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation. Risk C: Monitor therapy Amphetamines: May diminish the sedative effect of Antihistamines. Risk C: Monitor therapy Antacids: May decrease the excretion of Alpha-/Beta-Agonists.

Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract. Risk D: Consider therapy modification ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. Risk C: Monitor therapy Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. Risk C: Monitor therapy Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Risk C: Monitor therapy Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists. Risk D: Consider therapy modification Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated. Risk D: Consider therapy modification Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Risk C: Monitor therapy Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Risk C: Monitor therapy Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium. Risk X: Avoid combination Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Risk D: Consider therapy modification Ethanol/Nutrition/Herb Interactions Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effect. Dietary Considerations Some products may contain sodium. Pricing: U.S. (Medi-Span®)

Liquid (J-Tan D PD Oral) 1-7.5 mg/mL (30 mL): $69.66 International Brand Names Dimetapp (MX) Mechanism of Action Brompheniramine maleate is an antihistamine with H 1 -receptor activity; pseudoephedrine, a sympathomimetic amine and isomer of ephedrine, acts as a decongestant in respiratory tract mucous membranes with less vasoconstrictor action than ephedrine in normotensive individuals. Pharmacodynamics/Kinetics See individual agents. Use of UpToDate is subject to the Subscription and License Agreement . Topic 8820 Version 46.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.4 - C21.36 Licensed to: Southeast Alabama Med Ctr | Support Tag: [0502-201.77.166.39-9D3D6B0F7E-S244013.14]